Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>CYB004 completes patient enrollment to push Phase 2 study toward the finish line.</li><li>Cybin has confirmed that it has enrolled its 36th and final patient for its Phase 2 CYB004 program to evaluate the safety and efficacy of its proprietary short-acting deuterated version of DMT for the treatment of generalized anxiety disorder (GAD) at six and 12 weeks after first dose.</li><li>Top-line data of the Phase 2 study is expected to be forthcoming in 1Q26.</li></ul>

CYB004 completes patient enrollment to push Phase 2 study toward the finish line.Cybin has confirmed that it has enrolled its 36th and final patient for its Phase 2 CYB004 program to evaluate the safety and efficacy of its proprietary short-acting deuterated version of DMT for the treatment of generalized anxiety disorder (GAD) at six and 12 weeks after first dose.Top-line data of the Phase 2 study is expected to be forthcoming in 1Q26.

Cybin, Inc: CYB004 Completes Enrollment; Top-Line Read Expected in 1Q26